Theravance biopharma inc

Major-Pharmaceuticals

TBPH


Ugland House
George Town , KY1-1104

Executive/
Director

Price

  • Last Close
  • $ 9.29
    $ -0.01 -0.11 %
    Jan 3, 2025
  • 52-Week High/Low
  • $11.59 - $7.66
  • YTD
  • 0%

  • Trading Volume
  • 2,718
  • Market Cap Full
  • $ 462.6M
  • Shares Outstanding
  • 49.8M
    Nov 1, 2023
2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Q1 15.5% -13.1% -11.4% -5% 16.2% -13.5% -3.3% -20.3% -1.3% -
Q2 8.2% -3.4% -30.9% 4% -28.9% -5.2% -4.6% -7.9% - -
Q3 -14.1% 43.1% 19.4% 8% -49% 11.9% -16.6% -18.7% - -
Q4 -21.1% -23% 33.4% 18.8% 49.3% 10.7% 29.5% -5.8% - -
J F M A M J J A S O N D
2026 - - - - - - - - - - - -
2025 -1.3% - - - - - - - - - - -
    2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
    95%-13%-8%2%-33%-37%2%0%-16%-1%0%

Earnings

2017 2018 2019 2020 2021 2022 2023
Q1 1.27 -1.22 -1.32 -1.4 -1.24 -0.34 -0.35
Q2 1.27 -0.76 -0.72 -1 -0.8 -0.11 -0.28
Q3 1.27 -1.1 -1.05 -1.16 -0.48 12.14 -0.17
Q4 1.64 -0.91 -1.16 -0.9 -0.35 0.16 -
A 5.5 -4 -4.3 -4.5 -2.9 11.9 -0.8

Annual Returns

52 Week
High/Low

Annual
Earnings

Chart

Trading Volume

2018 2019 2020 2021 2022 2023
Mar - 55.6 62.5 64.3 74.7 62.9
Jun 54.9 56.1 63.1 65.3 76.1 57.8
Sep 55.1 56.6 63.5 73.5 76.4 52.8
Dec 55.4 56.8 64 73.7 67.4 49.8

Financial Ratios

20222021202020192018
Asset Management
Inventory / Stock Turnover - - - - -
Fixed Asset Turnover 0.2 0.6 2.3 3 2.2
Total Asset Turnover 0.1 0.2 0.2 0.2 0.1
Leverage
Debt Ratio - 1.5 1 0.7 0.4
Debt – Equity Ratio - -1.1 -1.2 -1 -4.4
Interest Coverage 0.1 4.4 14.9 15.8 10.4
Equity multiplier 0.5 -0.3 -0.1 -0.1 -0.5